A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Phase 2

Terminated

• Conditions: Non-Small Cell Lung Cancer
• Interventions: Drug: bevacizumab; Drug: sunitinib; Drug: paclitaxel; Drug: carboplatin

• Registration Number: NCT00434226
• Lead Sponsor: Genentech, Inc.

Brief Summary

This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and bevacizumab in patients with locally advanced, recurrent or metastatic NSCLC who have not received prior systemic therapy for NSCLC. All patients will have advanced, histologically or cytologically confirmed NSCLC (Stage IIIb with pleural effusions, Stage IV, or recurrent).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-02-11
• Study First Submitted QC: 2007-02-11
• Study First Posted: 2007-02-13
• Study Start: 2007-03
• Primary Completion: 2008-04
• Status Verified: 2009-07
• Results First Submitted: 2009-07-09
• Results First Submitted QC: 2009-07-09
• Last Update Submitted: 2009-07-09
• Results First Posted: 2009-08-21
• Last Update Posted: 2009-08-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• Signed Informed Consent Form
• Age ≥ 18 years
• Advanced histologically or cytologically confirmed NSCLC (Stage IIIb with malignant pleural or pericardial effusion, Stage IV, or recurrent)
• Measurable or non-measurable disease
• Patients with treated brain metastases are eligible if there is no evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period (brain imaging to be competed Day -7 to Day 1).
• Prior treatment for CNS disease as deemed appropriate by the treating physician
• ECOG performance status 0 or 1
• Ability and willingness to comply with study and follow-up procedures

Exclusion Criteria

• Prior systemic chemotherapy for metastatic disease
• Active malignancy other than lung cancer
• Current, recent, or planned participation in another experimental drug study
• Prior treatment with anti-VEGF agent or agents targeting similar pathways as sunitinib
• Adjuvant chemotherapy or prior combined modality neoadjuvant therapy (chemotherapy plus radiotherapy with or without surgery) within 6 months prior to Day 1 of Cycle 1
• Life expectancy of < 12 weeks
• Current, recent, or planned participation in an experimental drug study
• Inability to take oral medication or requirement of IV alimentation or total parenteral nutrition, or prior surgical procedures affecting absorption
• Inadequate organ function
• Known evidence of disseminated intravascular coagulopathy
• Active infection or fever > 38.5°C within 3 days prior to Day 1 of Cycle 1
• Untreated abnormal thyroid function tests as defined by institutional standards (patients with controlled hypothyroidism are eligible for study participation)
• Any other medical condition(s) (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results
• Intrathoracic lung carcinoma of squamous cell histology
• Known CNS disease except for treated brain metastases
• Inadequately controlled hypertension
• Prior history of hypertensive crisis or hypertensive encephalopathy
• New York Heart Association (NYHA) Class II or greater CHF
• History of myocardial infarction or unstable angina within 12 months prior to Day 1 of Cycle 1
• History of stroke or transient ischemic attack within 12 months prior to Day 1 of Cycle 1
• Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1 of Cycle 1
• History of hemoptysis within 1 month prior to Day 1 of Cycle 1
• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for major surgical procedure during the course of the study
• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of Cycle 1
• History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of Cycle 1
• Serious, non-healing wound, active ulcer, or untreated bone fracture
• Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening
• Known hypersensitivity to any component of bevacizumab or sunitinib
• Pregnancy (positive pregnancy test) or lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Bevacizumab + Carboplatin/Paclitaxel	paclitaxel	-
Bevacizumab + Carboplatin/Paclitaxel + Sunitinib	bevacizumab	-
Bevacizumab + Carboplatin/Paclitaxel + Sunitinib	sunitinib	-
Bevacizumab + Carboplatin/Paclitaxel + Sunitinib	paclitaxel	-
Bevacizumab + Carboplatin/Paclitaxel + Sunitinib	carboplatin	-
Bevacizumab + Carboplatin/Paclitaxel	bevacizumab	-
Bevacizumab + Carboplatin/Paclitaxel	carboplatin	-

Primary Outcome Measures

Name	Time	Method
Best Response	From randomization until disease progression/recurrence	The best overall response is the best response, per RECIST criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.

Secondary Outcome Measures

Name	Time	Method
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction	60 days following the last administration of study treatment	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
Incidence of Grade ≥ 3 Adverse Events	60 days following the last administration of study treatment	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
Serious Adverse Events	60 days following the last administration of study treatment	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption	60 days following the last administration of study treatment	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0